Skip to main content

Table 3 Mean cost (in euros) and mean effectiveness (in QALY) per patient for each maintenance strategy, during the different management periods after induction chemotherapy

From: Cost-utility analysis of maintenance therapy with gemcitabine or erlotinib vsobservation with predefined second-line treatment after cisplatin–gemcitabine induction chemotherapy for advanced NSCLC: IFCT-GFPC 0502-Eco phase III study

 

Observation (n = 155)

Gemcitabine (n = 154)

Erlotinib (n = 155)

Parameter

Cost

QALY

Cost

QALY

Cost

QALY

Maintenance

€702

0.202

€8,487

0.256

€10,551

0.241

Second-line

€7,449

0.114

€6,412

0.103

€6,637

0.103

Palliative care

€14,582

0.229

€13,497

0.260

€14,741

0.251

Total

€22,734

0.545

€28,397

0.619

€31,928

0.595

Difference from observation

€5,663

0.074

€9,195

0.050

ICER

76,625 [44,212 – 188,887]

184,733 [94,559 – 1,186,736]

  1. Legend: ICER, incremental cost-effectiveness ratio; QALY, quality-adjusted life year.